Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990’s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology....
Ready to explore how data-driven insights can accelerate your pharmaceutical research? Connect with our team to discuss your goals.
We use cookies to collect information to help us personalize your experience and improve the functionality and performance of our site. By continuing to use our site, you consent to our use of cookies. For more information, see our Cookies Policy.